for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Madrigal Pharmaceuticals Inc

MDGL.OQ

Latest Trade

99.16USD

Change

0.90(+0.92%)

Volume

38,977

Today's Range

96.43

 - 

101.82

52 Week Range

82.39

 - 

231.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
98.26
Open
98.93
Volume
38,977
3M AVG Volume
3.99
Today's High
101.82
Today's Low
96.43
52 Week High
231.09
52 Week Low
82.39
Shares Out (MIL)
15.43
Market Cap (MIL)
1,515.79
Forward P/E
-16.64
Dividend (Yield %)
--

Latest Developments

More

Madrigal Pharmaceuticals Reports 2019 Q2 Loss Per Share $1.28

Madrigal Pharmaceuticals Inc - QTRLY Net Loss $0.98 Per Share

Madrigal Pharmaceuticals To Present Additional Analyses Of Data From Phase 2 NASH Study With MGL-3196

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Industry

Biotechnology & Drugs

Contact Info

200 Barr Harbor Dr Ste 400

+1.404.3809263

http://www.madrigalpharma.com

Executive Leadership

Paul A. Friedman

Chairman of the Board, Chief Executive Officer

Marc R. Schneebaum

Chief Financial Officer, Senior Vice President

Rebecca A. Taub

President of Research & Development, Director

Frederick B. Craves

Lead Independent Director

Kenneth M. Bate

Independent Director

Key Stats

2.17 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-5.070

2017

-2.540

2018

-2.220

2019(E)

-5.905
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-11.61
Return on Equity (TTM)
-11.39

Latest News

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

Madrigal Pharma explores sale: Bloomberg

Madrigal Pharmaceuticals Inc <MDGL.O> is exploring a sale, Bloomberg reported on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

Madrigal Pharma more than doubles after liver drug study success

Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.

Madrigal Pharma's liver disease drug succeeds in mid-stage trial

Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.

BRIEF-Madrigal Pharmaceuticals Reports Qtrly Loss Per Share Of $0.45

* MADRIGAL PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS

BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​

* MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

BRIEF-Madrigal Pharmaceuticals Prices Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Madrigal Pharma Announces Proposed Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196

* Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia

BRIEF-Madrigal Pharmaceuticals reports qtrly loss per share $0.69

* Madrigal Pharmaceuticals reports 2017 second quarter financial results

BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH

* Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH

BRIEF-Madrigal Pharma announces $35 million private placement offering

* Madrigal pharmaceuticals announces $35 million private placement offering

BRIEF-Madrigal Pharmaceuticals says DSMC for clinical studies of MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial

* Madrigal Pharmaceuticals - on May 26, DSMC for clinical studies of co's MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial

BRIEF-Madrigal Pharmaceuticals qtrly loss per share $0.50

* Madrigal Pharmaceuticals reports 2017 first quarter financial results

BRIEF-Madrigal Pharmaceuticals Q4 loss per share $0.67

* Madrigal Pharmaceuticals reports 2016 fourth quarter and year-end financial results, reviews key corporate achievements and provides update on lead clinical-stage compound, MGL-3196

BRIEF-Madrigal Pharmaceuticals initiates Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH)

* Madrigal Pharmaceuticals announces the initiation of a Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH) Source text for Eikon: Further company coverage:

BRIEF-Madrigal Q3 loss per share $1.34

* Madrigal reports third quarter 2016 financial results Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up